OncoSynergy is a privately-held biotech company with a monoclonal antibody drug platform that is being developed for glioblastoma, the most aggressive form of brain cancer.
There is a great interview in Science Exchange this month with OncoSynergy's founder and CEO Shawn Carbonell, MD, PhD, and his wife, Anne-Marie Carbonell, MD, Vice President of Clinical Development.
In the interview, Shawn and Anne-Marie discuss their work on a drug that could be a game changer for patients with glioblastoma. They also talk about their involvement in the Race for Hope DC - the world's largest brain tumor community event, co-hosted by Accelerate Brain Cancer Cure and the National Brain Tumor Society. OncoSynergy is the Social Media Sponsor of the 2014 Race for Hope DC.
Click HERE for the full article in Science Exchange.